Invited reviewBortezomib in plasmablastic lymphoma: A glimpse of hope for a hard-to-treat disease

- Plasmablastic lymphoma (PBL) is a rare, CD20-negative aggressive lymphoma associated with a poor survival.
- Bortezomib is a proteasome inhibitor that could, in addition to chemotherapy, improve outcomes in PBL.
- Multicenter prospective studies are needed to evaluate the efficacy of bortezomib-based regimens in PBL.

Plasmablastic lymphoma (PBL) is a rare and hard to treat disease. With current standard chemotherapeutic regimens, PBL is associated with a median overall survival of 12-15 months. We performed a systematic review of the literature through March 31, 2017 looking for patients with a diagnosis of PBL who were treated with bortezomib, alone or in combination. We identified 21 patients, of which 11 received bortezomib in the frontline setting and 10 received bortezomib in the relapsed setting. Eleven patients were HIV-positive and 10 were HIV-negative. The overall response rate to bortezomib-containing regimens was 100% in the frontline setting and 90% in the relapsed setting. Furthermore, the 2-year overall survival of patients treated upfront was 55%, and the median OS in relapsed patients was 14 months. Although the sample size is small, we believe our results are encouraging and should serve as rationale to investigate bortezomib-based regimens in patients with PBL.